PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

• A. Krishnan,
• A. K. Nooka,
• A. Chari,
• A. Garfall,
• T. Martin,
• S. Nair,
• X. Lin,
• K. Qi,
• A. Londhe,
• L. Pei,
• E. Ammann,
• R. Kobos,
• J. Smit,
• T. Parekh,
• M. Slavcev,
• S. Usmani

Affiliations

A. Krishnan

1 City of Hope Comprehensive Cancer Center, Duarte, CA

A. K. Nooka

2 Winship Cancer Institute, Emory University, Atlanta, GA

A. Chari

3 Mount Sinai School of Medicine, New York, NY

A. Garfall

4 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

T. Martin

5 University of California, San Francisco, CA, United States of America

S. Nair

6 Janssen Pharmaceutica NV, Beerse, Belgium

X. Lin

7 Janssen Global Services, Horsham, PA

K. Qi

8 Janssen Research & Development, Titusville, NJ

A. Londhe

8 Janssen Research & Development, Titusville, NJ

L. Pei

9 Janssen Research & Development

E. Ammann

10 Janssen Global Services, Raritan, NJ

R. Kobos

9 Janssen Research & Development

J. Smit

11 Janssen Research & Development, Spring House, PA

T. Parekh

12 Janssen Research & Development, Bridgewater, NJ

M. Slavcev

10 Janssen Global Services, Raritan, NJ

S. Usmani

13 Memorial Sloan Kettering Cancer Center, New York, NY, United States of America